Tune Therapeutics
@tunetx-news.bsky.social
The Duke Chronicle celebrates our recent financing announcement, and talks to TuneTx leaders Charles Gerbsach and Derek Jantz about their Duke connections
dukechronicle.com/article/2025...
dukechronicle.com/article/2025...
Duke professor-led biotech company raises $175 million to advance epigenome editing therapy clinical trials
The company will use the funding to advance clinical trials for Tune-401, the epigenetic silencing drug for treating chronic Hepatitis B — a viral infection that damages the liver and affects millions...
dukechronicle.com
February 7, 2025 at 12:14 AM
The Duke Chronicle celebrates our recent financing announcement, and talks to TuneTx leaders Charles Gerbsach and Derek Jantz about their Duke connections
dukechronicle.com/article/2025...
dukechronicle.com/article/2025...
This week, be sure to catch TuneTx Co-Founders Charles Gersbach and Fyodor Urnov - along with Tune VP & Head of Research Blythe Sather - at PMWC 2025. Their 'Beyond the Genome' panel event on the future potential of epigenetic medicine. #PMWC2025 #geneticmedicine #epigenome
February 7, 2025 at 12:14 AM
This week, be sure to catch TuneTx Co-Founders Charles Gersbach and Fyodor Urnov - along with Tune VP & Head of Research Blythe Sather - at PMWC 2025. Their 'Beyond the Genome' panel event on the future potential of epigenetic medicine. #PMWC2025 #geneticmedicine #epigenome
Tune Therapeutics' CSO, Derek Jantz, highlights major innovations like epigenome editing for precise gene expression and advances in LNP mRNA tech. Watch here: bioprocessonline.com/doc/tune-the... #GeneTherapy #Biotech
January 29, 2025 at 2:05 AM
Tune Therapeutics' CSO, Derek Jantz, highlights major innovations like epigenome editing for precise gene expression and advances in LNP mRNA tech. Watch here: bioprocessonline.com/doc/tune-the... #GeneTherapy #Biotech
Reposted by Tune Therapeutics
Exclusive: A rarity in genetic medicine these days: Tune Therapeutics has raised over $175M in a Series B, its leaders told me just as #JPM25 gets going
The megaround kicks off a critical 2025 for the field, as epigenetic editing enters human testing
endpts.com/tune-therape...
The megaround kicks off a critical 2025 for the field, as epigenetic editing enters human testing
endpts.com/tune-therape...
Exclusive: Bucking gene-editing downturn, Tune raises $175M to bring epigenetic editing to clinic
Tune Therapeutics raises $175M Series B for epigenetic editing, with hepatitis B drug Tune-401 in the clinic. NEA, Yosemite, Regeneron Ventures led funding.
endpts.com
January 12, 2025 at 1:51 PM
Exclusive: A rarity in genetic medicine these days: Tune Therapeutics has raised over $175M in a Series B, its leaders told me just as #JPM25 gets going
The megaround kicks off a critical 2025 for the field, as epigenetic editing enters human testing
endpts.com/tune-therape...
The megaround kicks off a critical 2025 for the field, as epigenetic editing enters human testing
endpts.com/tune-therape...
Tune Therapeutics Completes Over $175M in Series B Financing to Advance Field-Leading Epigenome Editing Programs
www.businesswire.com/news/home/20...
www.businesswire.com/news/home/20...
Tune Therapeutics Completes Over $175M in Series B Financing to Advance Field-Leading Epigenome Editing Programs
Leading epigenome editing company Tune Therapeutics (Tune) today announced the completion of over $175M in financing led by New Enterprise Associates,
www.businesswire.com
January 13, 2025 at 8:30 PM
Tune Therapeutics Completes Over $175M in Series B Financing to Advance Field-Leading Epigenome Editing Programs
www.businesswire.com/news/home/20...
www.businesswire.com/news/home/20...
Featured in Drug Discovery World - At #AASLD2024, Principal Scientist Brian Cosgrove unveiled new data on Tune-401, their liver-targeting LNP-RNA epi-silencing drug. www.ddw-online.com/preclinical-... #HBV #Epigenetics
Preclinical data suggests functional cure for HBV - Drug Discovery World (DDW)
Epigenome editing company Tune Therapeutics has showcased new data at the American Association for the Study of Liver Diseases (AASLD) conference, in support of its drive to develop a lasting, functio...
www.ddw-online.com
January 13, 2025 at 12:53 PM
Featured in Drug Discovery World - At #AASLD2024, Principal Scientist Brian Cosgrove unveiled new data on Tune-401, their liver-targeting LNP-RNA epi-silencing drug. www.ddw-online.com/preclinical-... #HBV #Epigenetics